Gabapentin
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
Gabapentin: Preliminary Assessment — Insufficient Data for Repurposing Prediction
One-Sentence Summary
Gabapentin (DrugBank: DB00996) is a well-known anticonvulsant and neuropathic pain agent used globally for epilepsy and nerve pain management. However, the TxGNN model has not yet generated any predicted new indications for this drug, and critical data gaps — including mechanism of action, local regulatory information, and safety profiles — remain unresolved.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available in current dataset |
| Predicted New Indication | None (no predictions generated) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction not yet available |
| Philippines Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, no TxGNN repurposing prediction has been generated for Gabapentin. Without a predicted new indication, a mechanistic plausibility analysis cannot be performed at this time.
Detailed mechanism of action data is not available in the current evidence pack. Based on publicly known information, Gabapentin is a structural analogue of gamma-aminobutyric acid (GABA) that binds to the α2δ subunit of voltage-gated calcium channels, reducing excitatory neurotransmitter release. It is widely approved internationally for the adjunctive treatment of partial seizures (epilepsy) and for the management of neuropathic pain conditions such as postherpetic neuralgia. These mechanisms could theoretically extend to other neurological or pain-related conditions, but no specific repurposing prediction has been made by the model.
This assessment is currently blocked by multiple data gaps: the absence of Philippines FDA registration data (the drug is not marketed locally), the lack of TxGNN prediction output, and missing safety labelling information. All of these must be resolved before a meaningful repurposing evaluation can proceed.
Clinical Trial Evidence
Currently no related clinical trials registered for a repurposing indication, as no new indication has been predicted by the model.
Literature Evidence
Currently no related literature available for a repurposing indication, as no new indication has been predicted by the model.
Philippines Market Information
Gabapentin is not currently marketed in the Philippines. No FDA Philippines registrations were found in the dataset (0 licenses).
Safety Considerations
Please refer to the package insert for safety information. All safety fields (key warnings, contraindications, and drug–drug interactions) are currently unavailable in this evidence pack and require supplementation from the Philippines FDA or international labelling sources.
Conclusion and Next Steps
Decision: Hold
Rationale: No repurposing prediction has been generated by TxGNN, the drug is not marketed in the Philippines, and critical safety and regulatory data are missing. There is insufficient information to evaluate any repurposing opportunity at this time.
To proceed, the following is needed:
- Run TxGNN prediction pipeline for Gabapentin (DB00996) to generate candidate new indications
- Obtain Philippines FDA registration data, or confirm whether Gabapentin products are available under alternative regulatory pathways
- Retrieve mechanism of action (MOA) data from DrugBank API (remediation identified in data gap DG002)
- Obtain package insert safety information — warnings, contraindications, and DDI data (remediation identified in data gap DG001)
- Collect clinical trial and literature evidence once a predicted indication is available
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.